Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.

• In silico structural modeling suggested that ozoralizumab (OZR) can simultaneously bind to TNFα trimer and HSA. • OZR showed potent TNFα-neutralizing activity by bivalently binding to TNFα trimer in the presence of excess amount of HSA. • OZR had long plasma half-life by utilizing recycling of HSA via FcRn by binding to HSA with anti-HSA NANOBODY® molecule. [ABSTRACT FROM AUTHOR]